Showing 161 - 180 results of 232,604 for search '(( 5 non decrease ) OR ( 10 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.78s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, visits declined from 10.4 ± 4.5 preoperatively to 7.1 ± 2.2, 3.4 ± 1.3, and 2.6 ± 1.0 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g008" target="_blank">Fig 8</a>).…”
  5. 165

    rVλ6Wil fibrils cause a decrease in cardiomyocytes MTT reduction without inducing cell death. by Helen P. McWilliams-Koeppen (116503)

    Published 2015
    “…(C) Cell number, quantified using crystal violet (black) did not decrease over 72 h of incubation with 1 μM rVλ6Wil fibrils despite a decrease in MMT reduction (grey; n = 3 samples per time point). …”
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170

    Time allocation may not decrease with price for a non-linear microscopic utility of leisure. by Ritwik K. Niyogi (427932)

    Published 2014
    “…We normalised by the trial duration of 25 price, instead of simply normalizing by the price, to emphasise that <i>TA</i> is a macroscopic quantitity and to be consistent with the procedure in the example data <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1003894#pcbi.1003894.s001" target="_blank">Figure S1</a>.…”
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  16. 176

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  17. 177
  18. 178

    Sarcopenia as an Independent Risk Factor for Decreased BMD in COPD Patients: Korean National Health and Nutrition Examination Surveys IV and V (2008-2011) by Dong-Won Lee (2208223)

    Published 2016
    “…</p><p>Methods</p><p>COPD patients aged 50 or older with qualifying spirometry and dual-energy X-ray absorptiometry data were from participants in the Korean National Health and Nutrition Examination Surveys IV and V (2008–2011).</p><p>Results</p><p>There were 286 (33.3%) subjects in the sarcopenia group and 572 (66.7%) in the non-sarcopenia group. …”
  19. 179
  20. 180